{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:38:59Z","timestamp":1788745139701,"version":"build-2803163510"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complications in TB patients. This study investigates the co-treatment of MDR\/RR-TB and HCV, using data from the TB-PRACTECAL trial. Data were collected as part of the TB-PRACTECAL clinical trial. All participants were screened for HCV at baseline. Participants who were HCV antibody positive and those who were treated for hepatitis C with Direct Acting Antivirals (DAAs) were extracted and compared to overall cohort characteristics. The characteristics of participants concomitantly treated with direct-acting antivirals are described including hepatitis treatment outcomes and adverse events. Among 552 participants from Belarus, Uzbekistan, and South Africa, 24 (4.3%) were HCV antibody positive. Unfavourable TB treatment outcomes were noted in 106\/523 (22%) of the HCV-negative, 8\/18 (44%) of the HCV-seropositive, and 2\/7 (29%) of HCV-confirmed participants treated with DAAs. Of the six participants who received concurrent HCV and MDR\/RR TB treatment, three were cured of HCV and three had no post-treatment HCV RNA test, five completed TB treatment and one discontinued treatment due to a severe adverse reaction. Concurrent treatment of MDR-TB and HCV, including in HIV patients, showed promising outcomes with no significant adverse events. The findings support the potential benefits of integrating HCV care into MDR-TB management.<\/jats:p>","DOI":"10.1371\/journal.pgph.0003057","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:24:22Z","timestamp":1727198662000},"page":"e0003057","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, treatment, and outcomes of hepatitis C in an MDR\/RR-TB trial cohort"],"prefix":"10.1371","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9737-8664","authenticated-orcid":true,"given":"Jocelyn","family":"Jansen van Vuuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Crocker-Buque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzmitry","family":"Viatushka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0952-7669","authenticated-orcid":true,"given":"Ruzilya","family":"Usmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bern-Thomas","family":"Nyang\u2019wa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiza","family":"Parpieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Liverko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Solodovnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-7813","authenticated-orcid":true,"given":"Animesh","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"pgph.0003057.ref001","volume-title":"Global hepatitis report","author":"WHO","year":"2017"},{"key":"pgph.0003057.ref002","volume-title":"Global tuberculosis report","author":"WHO","year":"2018"},{"key":"pgph.0003057.ref003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12985-020-01385-z","article-title":"Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study.","volume":"17","author":"B Feleke","year":"2020","journal-title":"Virol j."},{"key":"pgph.0003057.ref004","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jhep.2019.10.018","article-title":"High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients","volume":"72","author":"KJ Seung","year":"2020","journal-title":"J Hepatol"},{"key":"pgph.0003057.ref005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(16)30856-X","article-title":"The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia","volume":"388","author":"FL Altice","year":"2016","journal-title":"Lancet"},{"key":"pgph.0003057.ref006","first-page":"101938","article-title":"Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis.","volume":"58","author":"ID Olaru","year":"2023","journal-title":"eCliniM"},{"key":"pgph.0003057.ref007","volume-title":"WHO consolidated guidelines on Tuberculosis. Drug Resistant Tuberculosis treatment, module 4.","author":"WHO","year":"2022"},{"key":"pgph.0003057.ref008","volume-title":"Global report on HIV, viral hepatitis and sexually transmitted infections","author":"WHO","year":"2021"},{"issue":"2","key":"pgph.0003057.ref009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcma.2017.10.002","article-title":"The susceptibility of anti-tuberculosis drug induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis","volume":"81","author":"TE Chang","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"pgph.0003057.ref010","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5588\/ijtld.15.0668","article-title":"Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis","volume":"20","author":"SS Lee","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"pgph.0003057.ref011","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"JR Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"pgph.0003057.ref012","article-title":"Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis","author":"N Lomtadze","journal-title":"PLoS one"},{"key":"pgph.0003057.ref013","first-page":"616","article-title":"Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment","volume":"14","author":"Y Chien J","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"pgph.0003057.ref014","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1378\/chest.06-2042","article-title":"Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy.","volume":"131","author":"S Kwon Y","year":"2007","journal-title":"Chest"},{"key":"pgph.0003057.ref015","first-page":"2984","article-title":"High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons","volume":"46","author":"E Gurbanova","year":"2015","journal-title":"Eur Respir J"},{"key":"pgph.0003057.ref016","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01215-19","article-title":"A pharmacology perspective on simultaneous tuberculosis and hepatitis C treatment","volume":"63","author":"RR Kempker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pgph.0003057.ref017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5588\/ijtld.22.0403","article-title":"Co-administration of treatment for drug-resistant TB and Hepatitis C","volume":"27","author":"ID Olaru","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"pgph.0003057.ref018","article-title":"Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe","author":"N. Melikyan","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"pgph.0003057.ref019","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/s12879-019-4494-1","article-title":"Hepatitis C viral infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis","volume":"19","author":"M Musso","year":"2019","journal-title":"BMC Infect dis"},{"issue":"6","key":"pgph.0003057.ref020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jinf.2022.03.004","article-title":"Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study.","volume":"84","author":"S Tunesi","year":"2022","journal-title":"J Infect"},{"issue":"25","key":"pgph.0003057.ref021","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24 Week, All Oral Regimen for Rifampin Resistant Tuberculosis.","volume":"387","author":"B. T. Nyang\u2019wa","year":"2022","journal-title":"NEJM"},{"key":"pgph.0003057.ref022","volume-title":"Public call for experts with experience in the co-administration of treatment for drug-resistant tuberculosis and hepatitis C","author":"WHO","year":"2023"},{"key":"pgph.0003057.ref023","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13063-022-06331-8","article-title":"TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II\u2013III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis","volume":"23","author":"C Berry","year":"2022","journal-title":"Trials"},{"issue":"2","key":"pgph.0003057.ref024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5588\/pha.22.0002","article-title":"Integrating hepatitis C treatment into multi-drug resistant TB care.","volume":"12","author":"O Kirakosyan","year":"2022","journal-title":"PHA"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:24:36Z","timestamp":1727198676000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003057"}},"subtitle":[],"editor":[{"given":"N. Sarita","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0003057","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}